Nitric oxide and vascular remodeling: Spotlight on the kidney

Kidney International

Volumn 72, Issue SUPPL. 106, 2007, Pages S9-

  Eberhardt, W ^a   Pfeilschifter, J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Extracellular matrix; Inflammation; Perivascular tissue remodeling; Renal fibrosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; ENZYME REGULATION; HUMAN; KIDNEY; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 34547476097     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002381     Document Type: Conference Paper

References (119)

1. Newby CA. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
2. Newby AC, George SJ. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 1993; 27: 1173-1183.
3. Isenberg JS, Ridnour LA, Espey MG et al. Nitric oxide in wound-healing. Microsurgery 2005; 25: 442-451.
4. Millatt LJ, Abdel-Rahman EM, Siragy HM. Angiotensin II and nitric oxide: a question of balance. Regul Pept 1999; 81: 1-10.
5. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
6. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-635.
7. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69: 614-624.
8. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
9. Boffa JJ, Lu Y, Placier S et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-1144.
10. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 1993; 118: 712-719.
11. Chatziantoniou C, Boffa JJ, Tharaux PL et al. Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol 2004; 85: 1-11.
12. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
13. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301.
14. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003; 14: S246-S249.
15. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37: 490-496.
16. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-452.
17. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 1990; 16: 477-483.
18. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
19. Millatt LJ, Abdel-Rahman EM, Siragy HM. Angiotensin II and nitric oxide: a question of balance. Regul Pept 1999; 81: 1-10.
20. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
21. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 1998; 101: 2780-2789.
22. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281.
23. Baylis C, Bloch J. Nitric oxide (NO) in renal physiology and pathophysiology. Nephrol Dial Transplant 1996; 11: 1955-1957.
24. Myers PR, Webel R, Thondapu V et al. Restenosis is associated with decreased coronary artery nitric oxide synthase. Int J Cardiol 1996; 55: 183-191.
25. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
26. Williams SB, Cusco JA, Roddy MA et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
27. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
28. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244-254.
29. Pfeilschifter J, Eberhardt W, Huwiler A. Nitric oxide and mechanisms of redox signaling. J Am Soc Nephrol 2003; 14: S237-S240.
30. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666.
31. Kashgarian M, Sterzel RB. The pathobiology of the mesangium. Kidney Int 1992; 41: 524-529.
32. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001; 59: 804-819.
33. Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005; 25: 553-569.
34. Yoshioka K, Tohda M, Takemura T et al. Distribution of type I collagen in human kidney diseases in comparison with type III collagen. J Pathol 1990; 162: 141-148.
35. Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 1995; 26: 141-146.
36. Pescucci C, Longo I, Bruttini M et al. Type-IV collagen related diseases. J Nephrol 2003; 16: 314-316.
37. Jiang Z, Seo JY, Ha H et al. Reactive oxygen species mediate TGF-β1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 2003; 309: 961-966.
38. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
39. Peters H, Border WA, Noble NA. -Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 1999; 55: 2264-2273.
40. Beck KF, Eberhardt W, Frank S et al. Inducible NO synthase: role in cellular signalling. J Exp Biol 1999; 202: 645-653.
41. Feil R, Feil S, Hofmann F. A heretical view on the role of NO and cGMP in vascular proliferative diseases. Trends Mol Med 2005; 11: 71-75.
42. Hofmann F, Biel M, Feil R, Kleppisch T. Mouse models of NO/natriuretic peptide/cGMP kinase signaling. In: Offermanns S, Hein L (eds). Handbook of Experimental Pharmacology, vol 159. Springer-Verlag: Heidelberg, 2004, pp 95-130.
43. Vaandrager AB, de Jonge HR. Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 1996; 157: 23-30.
44. Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995; 369: 136-139.
45. Kroncke KD. Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation. Antioxid Redox Signal 2001; 3: 565-575.
46. Gu Z, Kaul M, Yan B et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002; 297: 1186-1190.
47. Schindler H, Bogdan C. NO as a signaling molecule: effects on kinases. Int Immunopharmacol 2001; 1: 1443-1455.
48. Pfeilschifter J, Eberhardt W, Huwiler A. Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur J Pharmacol 2001; 429: 279-286.
49. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11: 66-75.
50. Pfeilschifter J, Eberhardt W, Beck KF. Regulation of gene expression by nitric oxide. Pflugers Arch 2001; 442: 479-486.
51. Kim H, Shim J, Han PL, Choi EJ. Nitric oxide modulates the c-Jun N-terminal kinase/stress-activated protein kinase activity through activating c-Jun N-terminal kinase kinase. Biochemistry 1997; 36: 13677-13681.
52. Lander HM, Ogiste JS, Pearce SF et al. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J Biol Chem 1995; 270: 7017-7020.
53. Lander HM, Sehajpal PK, Novogrodsky A. Nitric oxide signaling: a possible role for G proteins. J Immunol 1993; 151: 7182-7187.
54. Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol 2003; 23: 26-36.
55. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993; 92: 1366-1372.
56. Yu L, Border WA, Anderson I et al. Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66: 1774-1784.
57. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
58. Fern RJ, Yesko CM, Thornhill BA et al. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999; 103: 39-46.
59. Katoh M, Egashira K, Mitsui T et al. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000; 32: 73-83.
60. Kaikita K, Fogo AB, Ma L et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839-844.
61. Kaikita K, Schoenhard JA, Painter CA et al. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol 2002; 34: 617-627.
62. Hattori N, Mizuno S, Yoshida Y et al. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004; 164: 1091-1098.
63. Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am J Respir Cell Mol Biol 2006; 35: 705-713.
64. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71: 247-258.
65. Cucoranu I, Clempus R, Dikalova A et al. NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97: 900-907.
66. Bendall JK, Cave AC, Heymes C et al. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-296.
67. Deng X, Welch WJ, Wilcox CS. Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension 1996; 27: 1173-1179.
68. Higashi Y, Oshima T, Ono N et al. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995; 80: 2198-2202.
69. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627.
70. Ackermann A, Fernandez-Alfonso MS, Sanchez de Rojas R et al. Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol 1998; 124: 291-298.
71. Woessner Jr JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
72. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-22194.
73. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
74. Murphy G, Stanton H, Cowell S et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44.
75. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333.
76. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003; 384: 863-872.
77. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
78. Eberhardt W, Beeg T, Beck KF et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000; 57: 59-69.
79. Eberhardt W, Akool el-S, Rebhan J et al. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor α agonists is indirect and due to a NO-mediated reduction of mRNA stability. J Biol Chem 2002; 277: 33518-33528.
80. Akool el-S, Kleinert H, Hamada FM et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003; 23: 4901-4916.
81. Gonzalez-Avila G, Iturria C, Vadillo-Ortega F et al. Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology 1998; 66: 196-204.
82. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 1999; 19: 2871-2877.
83. Upchurch Jr GR, Ford JW, Weiss SJ et al. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg 2001; 34: 76-83.
84. Eagleton MJ, Peterson DA, Sullivan VV et al. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression. J Surg Res 2002; 104: 15-21.
85. Phillips PG, Birnby LM. Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1055-L1065.
86. Trachtman H, Futterweit S, Garg P et al. Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun 1996; 218: 704-708.
87. Jurasz P, Sawicki G, Duszyk M et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001; 61: 376-382.
88. Cheung PY, Sawicki G, Peliowski A et al. Nitric oxide inhibits the release of matrix metalloproteinase-2, but not platelet activation, during extracorporeal membrane oxygenation in adult rabbits. J Pediatr Surg 2003; 38: 534-538.
89. Chen HH, Wang DL. Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 2004; 65: 1130-1140.
90. Milkiewicz M, Kelland C, Colgan S, Haas TL. Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. J Cell Physiol 2006; 208: 229-237.
91. Gurjar MV, DeLeon J, Sharma RV, Bhalla RC. Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J Appl Physiol 2001; 91: 1380-1386.
92. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376.
93. Iwakura A, Shastry S, Luedemann C et al. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 2006; 113: 1605-1614.
94. Knipp BS, Ailawadi G, Ford JW et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-kappaB and activator protein-1 activity. J Surg Res 2004; 116: 70-80.
95. Sinha I, Hannawa KK, Ailawadi G et al. The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 2006; 20: 92-98.
96. Liu W, Rosenberg GA, Liu KJ. AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes. J Neurosci Res 2006; 84: 360-369.
97. Marcet-Palacios M, Graham K, Cass C et al. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther 2003; 307: 429-436.
98. Eberhardt W, Huwiler A, Beck KF et al. Amplification of IL-1β-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-κB and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 2000; 165: 5788-5797.
99. Yokoo T, Kitamura M. Dual regulation of IL-1β-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-κB and AP-1. Am J Physiol 1996; 270: F123-F130.
100. Yoshida M, Sagawa N, Itoh H et al. Nitric oxide increases matrix metalloproteinase-1 production in human uterine cervical fibroblast cells. Mol Hum Reprod 2001; 7: 979-985.
101. Ishii Y, Ogura T, Tatemichi M et al. Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int J Cancer 2003; 103: 161-168.
102. Zaragoza C, Balbin M, Lopez-Otin C, Lamas S. Nitric oxide regulates matrix metalloprotease-13 expression and activity in endothelium. Kidney Int 2002; 61: 804-808.
103. Eberhardt W, Beck KF, Pfeilschifter J. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 2002; 61: 20-30.
104. Akool el-S, Doller A, Muller R et al. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway. J Biol Chem 2005; 280: 39403-39416.
105. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-791.
106. Sharma AK, Mauer SM, Kim Y, Michael AF. Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. J Lab Clin Med 1995; 125: 754-761.
107. Engelmyer E, van Goor H, Edwards DR, Diamond JR. Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. J Am Soc Nephrol 1995; 5: 1675-1683.
108. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
109. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122: 923-932.
110. Wang S, Shiva S, Poczatek MH et al. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 2002; 277: 9880-9888.
111. Schmidt A, Geigenmueller S, Voelker W et al. Exogenous nitric oxide causes overexpression of TGF-β1 and overproduction of extracellular matrix in human coronary smooth muscle cells. Cardiovasc Res 2003; 58: 671-678.
112. Cattell V. Nitric oxide and glomerulonephritis. Kidney Int 2002; 61: 816-821.
113. Peters H, Border WA, Ruckert M et al. -Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 2003; 63: 1382-1392.
114. Weinberg JB, Granger DL, Pisetsky DS et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994; 179: 651-660.
115. Nozik ES, Huang YC, Piantadosi CA. -Arginine enhances injury in the isolated rabbit lung during hyperoxia. Respir Physiol 1995; 100: 63-74.
116. Neilly PJ, Kirk SJ, Gardiner KR et al. Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. Br J Surg 1995; 82: 1188-1191.
117. Zhang F, Casey RM, Ross ME, Iadecola C. Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 1996; 27: 317-323.
118. Kashem A, Endoh M, Yano N et al. Expression of inducible-NOS in human glomerulonephritis: The possible source is infiltrating monocytes/macrophages. Kidney Int 1996; 50: 392-399.
119. MacMillan-Crow LA, Crow JP, Kerby JD et al. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996; 93: 11853-11858.